Wells Fargo
PRLD icon

Wells Fargo’s Prelude Therapeutics PRLD Stock Holding History

Wells Fargo’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
+25,325
New +$110K ﹤0.01% 5404
2025
Q3 		– Sell
-297
Closed -$240 – 7326
2025
Q2 		$240 Sell
297
-7,615
-96% -$6.59K ﹤0.01% 6430
2025
Q1 		$6.08K Buy
7,912
+175
+2% +$163 ﹤0.01% 5991
2024
Q4 		$9.87K Buy
7,737
+1,684
+28% +$2.23K ﹤0.01% 5939
2024
Q3 		$12.5K Buy
6,053
+261
+5% +$1.21K ﹤0.01% 5737
2024
Q2 		$22.1K Buy
5,792
+518
+10% +$2.11K ﹤0.01% 5557
2024
Q1 		$25K Buy
5,274
+675
+15% +$2.63K ﹤0.01% 5511
2023
Q4 		$19.6K Buy
4,599
+963
+26% +$2.93K ﹤0.01% 5641
2023
Q3 		$11.2K Sell
3,636
-584
-14% -$2.19K ﹤0.01% 5777
2023
Q2 		$19K Buy
4,220
+4,042
+2,271% +$24.2K ﹤0.01% 5757
2023
Q1 		$1.01K Sell
178
-164
-48% -$1K ﹤0.01% 6372
2022
Q4 		$2.07K Sell
342
-29
-8% -$186 ﹤0.01% 6008
2022
Q3 		$2K Buy
371
+184
+98% +$1.24K ﹤0.01% 6180
2022
Q2 		$1K Buy
187
+87
+87% +$443 ﹤0.01% 6578
2022
Q1 		$1K Sell
100
-3,052
-97% -$27.9K ﹤0.01% 6845
2021
Q4 		$39K Buy
3,152
+3,109
+7,230% +$50.6K ﹤0.01% 6079
2021
Q3 		$2K Hold
43
– – ﹤0.01% 6587
2021
Q2 		$1K Sell
43
-972
-96% -$34.6K ﹤0.01% 6715
2021
Q1 		$44K Sell
1,015
-3,791
-79% -$251K ﹤0.01% 5874
2020
Q4 		$344K Buy
+4,806
New +$239K ﹤0.01% 4793

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Wells Fargo's PRLD Position: Q2 2026 in Review

Wells Fargo opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 25,325 shares worth $135K. The stake represents ﹤0.01% of the portfolio and ranks #5404 among its holdings. This is a return to the name: Wells Fargo previously reported a position in PRLD as recently as Q2 2025.

Wells Fargo first reported a position in PRLD in Q4 2020 and has held it in 20 quarters since. The position peaked at $344K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Wells Fargo held 25,325 shares of Prelude Therapeutics worth $135K as of Q2 2026.
  • Prelude Therapeutics was a new Wells Fargo position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5404 holding.
  • Wells Fargo first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Wells Fargo's Prelude Therapeutics position peaked at $344K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.